(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/018870 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 47/18* (2017.01)
A61K 9/08 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2022/040056

(22) International Filing Date:
11 August 2022 (11.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/232,299 12 August 2021 (12.08.2021) US
63/316,604 04 March 2022 (04.03.2022) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **BALL, Nicole**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **SLOEY, Christopher**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **LUERAS, Alexis**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **QIAN, Rulin**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).


(74) Agent: **HONG, Julie J.**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: ANTIBODY FORMULATIONS

FIGURE 1



(57) Abstract: Provided herein are liquid compositions comprising a high concentration of a monoclonal antibody, e.g., greater than about 100 mg/mL, which demonstrate storage -stability and reduced viscosity. In exemplary embodiments, the liquid composition comprises about less than about 400 mM arginine glutamate, and, in alternative exemplary embodiments, the liquid composition comprises proline and a buffer.

[Continued on next page]

WO 2023/018870 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*